Zenith Drugs Ltd

Zenith Drugs Ltd

₹ 81.1 -0.73%
24 Dec 11:04 a.m.
About

Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specializing in manufacturing and trading medicines, including generic drugs.[1]

Key Points

Product Portfolio[1]
ORS Powder;
Liquid Orals;
Ointments;
Liquid Externals;
Capsules

  • Market Cap 139 Cr.
  • Current Price 81.1
  • High / Low 154 / 52.8
  • Stock P/E 14.5
  • Book Value 39.6
  • Dividend Yield 0.62 %
  • ROCE 27.4 %
  • ROE 26.4 %
  • Face Value 10.0

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.1%

Cons

  • Company has high debtors of 187 days.
  • Working capital days have increased from 103 days to 155 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Mar 2024 Sep 2024
69 62 68
58 56 61
Operating Profit 11 6 7
OPM % 16% 9% 10%
-1 2 1
Interest 1 2 1
Depreciation 1 1 1
Profit before tax 8 6 6
Tax % 25% 32% 0%
6 4 6
EPS in Rs 4.75 2.24 3.34
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
78 72 92 115 132 130
71 64 85 105 115 117
Operating Profit 7 7 7 9 17 13
OPM % 9% 10% 8% 8% 13% 10%
0 0 1 1 1 3
Interest 1 1 2 2 3 3
Depreciation 1 1 1 1 1 1
Profit before tax 5 5 4 7 13 11
Tax % 30% 33% 27% 27% 28%
3 3 3 5 10 10
EPS in Rs 5.56 5.58
Dividend Payout % 0% 0% 0% 0% 9%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 22%
TTM: 15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 51%
TTM: 117%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 28%
Last Year: 26%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 0.40 0.40 0.40 0.40 17 17
Reserves 6 9 12 17 45 51
12 15 17 25 24 40
25 21 37 54 48 36
Total Liabilities 44 47 66 97 134 144
6 9 10 11 11 11
CWIP 3 0 0 0 4 21
Investments 0 0 0 0 0 0
35 37 56 86 119 112
Total Assets 44 47 66 97 134 144

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
3 -1 5 -4 -12
-5 -2 -3 -2 26
1 3 -1 6 -4
Net Cash Flow -0 -0 1 -0 9

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 119 119 128 157 187
Inventory Days 29 52 67
Days Payable 155 155 190
Cash Conversion Cycle -7 17 5 157 187
Working Capital Days 26 66 58 96 155
ROCE % 28% 24% 25% 27%

Shareholding Pattern

Numbers in percentages

1 Recently
Mar 2024Sep 2024
69.98% 69.98%
5.81% 0.42%
1.93% 0.00%
22.28% 29.60%
No. of Shareholders 1,1171,355

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents